LRRC18: A Potential Drug Target and Biomarker (G474354)

Target Name: LRRC18

NCBI ID: G474354

LRRC18

LRRC18: A Potential Drug Target and Biomarker

Introduction

Protein 18 (LRRC18) is a member of the Lrrc family, which are characterized by a specific repeat sequence (Leucine-rich repeat) in their amino acid sequence. Lrrc proteins are involved in various cellular processes, including cell signaling, DNA replication, and protein-protein interactions. The function and regulation of Lrrc18 is an active area of 閳ュ??濯焑search, and its potential implications as a drug target and biomarker are being explored.

Potential Drug Target

The protein 18 (LRRC18) is a potential drug target due to its unique structure and various cellular functions. One of the key features of Lrrc18 is its ability to interact with various protein partners, including other proteins and RNA molecules. This interaction is mediated by the unique repeat sequence, which is known as a leucine-rich repeat (LRR) and is composed of three conserved amino acids: Leucine, Lysine, and Glutamic acid.

The LRRC18-PRT (Protein-Protein interactions) domain is a key region of the protein that interacts with other proteins, including its partner, PRT (Protein-RNA interactions) domain-containing proteins. These interactions play a crucial role in regulating various cellular processes, including cell signaling, DNA replication, and protein-protein interactions. Therefore, targeting Lrrc18 and its interacting proteins may provide new insights into the mechanisms of these processes and may lead to the development of new therapeutic strategies.

Bioimmunimarker

LRRC18 is also a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. The unique structure of Lrrc18 and its interaction with other proteins make it an attractive target for diagnostic tools and therapeutic strategies.

One of the main advantages of Lrrc18 as a biomarker is its expression and/or levels are often affected by various diseases, which can be used as a diagnostic target. For example, overexpression of Lrrc18 has been shown to promote the growth and survival of cancer cells, and its downregulation has been shown to inhibit the growth of cancer cells. Therefore, measuring the expression and/or levels of Lrrc18 may provide a valuable diagnostic tool for cancer diagnosis and treatment.

Another potential application of Lrrc18 as a biomarker is its ability to interact with various proteins, including cancer cells and neurodegenerative diseases. Therefore, targeting Lrrc18 and its interacting proteins may provide new insights into the mechanisms of these diseases and may lead to the development of new therapeutic strategies.

Conclusion

LRRC18 is a unique and highly conserved protein that is involved in various cellular processes. Its ability to interact with other proteins and its unique structure make it an attractive target for drug development and biomarker research. The potential applications of Lrrc18 as a drug target and biomarker are being explored, and its future is shaping up to be a promising area of 閳ュ??濯焑search.

Protein Name: Leucine Rich Repeat Containing 18

Functions: May be involved in the regulation of spermatogenesis and sperm maturation

The "LRRC18 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LRRC18 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets